Table 3 Univariate and multivariate analyses in the primary cohort
From: Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature
Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age | 1.002 (0.986–1.018) | 0.853 |  |  |
T stage | ||||
 T1 | Referent |  |  |  |
 T2 | 1.631 (0.980–2.714) | 0.060 |  |  |
 T3 | 2.027 (1.060–3.876) | 0.033 |  |  |
 T4 | 5.748 (2.394–13.805) |  < 0.001 |  |  |
N stage | ||||
 N0 | Referent |  |  |  |
 N1 | 1.611 (1.004–2.585) | 0.048 |  |  |
 N2 | 2.282 (1.219–4.269) | 0.010 |  |  |
 N3 | 4.651 (2.425–8.921) |  < 0.001 |  |  |
 Nx | 15.987 (6.600–38.722) |  < 0.001 |  |  |
TNM stage | ||||
 I | Referent |  | Referent |  |
 II | 1.641 (0.850–3.167) | 0.140 | 1.589 (0.820–3.077 | 0.170 |
 III | 3.589 (1.824–7.061) | < 0.001 | 4.015 (2.010–8.020) | < 0.001 |
 Unknown | 13.559 (5.415–33.951) | < 0.001 | 12.054 (4.623–31.430) | < 0.001 |
ER status | ||||
 Negative | Referent |  |  |  |
 Positive | 0.562 (0.369–0.855) | 0.007 |  |  |
 Unknown | 1.097 (0.426–2.825) | 0.848 |  |  |
PR status | ||||
 Negative | Referent |  |  |  |
 Positive | 0.550 (0.369–0.821) | 0.003 |  |  |
 Unknown | 1.120 (0.442–2.838) | 0.811 |  |  |
Tumor subtype | ||||
 HR+/HER2− | Referent |  | Referent |  |
 HR+/HER2+ | 0.756 (0.339–1.687) | 0.495 | 0.792 (0.354–1.774) | 0.571 |
 HR−/HER2+ | 1.744 (0.624–4.872) | 0.289 | 0.924 (0.320–2.672) | 0.884 |
 TNBC | 2.038 (1.204–3.450) | 0.008 | 2.318 (1.359–3.955) | 0.002 |
 Unknown | 2.591 (1.572–4.269) |  < 0.001 | 1.922 (1.153–3.204) | 0.012 |
 Risk score | 2.718(1.903–3.884) |  < 0.001 | 2.975 (2.028–4.364) |  < 0.001 |